KAKhaled Alhwaishel

Khaled Alhwaishel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Khaled Alhwaishel has a total of 37 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Is cryoanalgesia superior to thoracic epidural analgesia for postoperative recovery after the nuss procedure? An updated meta-analysis

    by Kristine Santos, Clara Campoverde Fárez, Khaled Alhwaishel, Bezalel Hakkeem, Joo Young Belen Kim Kim, Gabriel Wekure Chanayire, Silvia M. West

    Kristine Santos, Clara Campoverde Fárez, Khaled Alhwaishel, Bezalel Hakkeem, Joo Young Belen Kim Kim, Gabriel Wekure Chanayire, and Silvia M. West. Korean J Pain -0001;0:. https://doi.org/10.3344/kjp.25189

  • Efficacy of Transcranial Direct Current Stimulation in Patients with Primary Progressive Aphasia: A Systematic Review and Updated Meta-analysis

    by Khaled Alhwaishel, Mariano Gallo Ruelas, Aisha Rizwan Ahmed, Victor Gonçalves Soares, Aishwarya Koppanatham, Jhon E. Bocanegra-Becerra, Elizabet Taylor Pimenta Weba, Anuraag Punukollu, Krish Kuhar, Gabriel de Moraes Mangas, et al.

    Background Primary progressive aphasia (PPA) is a group of dementias characterized by progressive loss of specific language functions with relative sparing of other cognitive domains. Transcranial direct current stimulation (tDCS) has been introduced as a potential therapeutic option for PPA. We aim to evaluate the efficacy of tDCS in improving cognitive and language functions in patients with PPA. Methods PubMed, Embase, Cochrane Library, and Web of Science were searched up to June 2024 to identify randomized controlled studies (RCTs) comparing tDCS vs sham procedure in patients with PPA. Results Our analysis encompassed ten RCTs comparing the efficacy of tDCS against sham treatment, with a total of 167 participants. Due to the crossover design implemented in several studies, 94.5% of participants received active tDCS, while 91.1% received the sham intervention. The findings demonstrated significant improvements immediately post-tDCS (SMD 0.29, 95% CI 0.003–0.57, p = 0.05, I2 = 19%) and sustained benefits after two months or more (SMD 0.51, 95% CI 0.10–0.92, p = 0.01, I2 = 11%) in the untrained naming task. Similarly, for the trained naming tasks, significant improvement was observed (SMD 0.96; 95% CI 0.27 to 1.65; p < 0.01; I2 = 0%), even after the end of the tDCS treatment, with effects persisting for up to two months. (SMD 0.64; 95% CI 0.15 to 1.13; p = 0.01; I2 = 8%). However, no significant improvements were observed in cognitive tasks, untrained comprehension, language, and trained semantic tasks. Conclusion Our findings suggest that tDCS may be efficacious in augmenting naming tasks both acutely and over a prolonged period of up to two months. However, its effects on overall cognitive performance remain inconclusive. Further robust trials are warranted to elucidate its impact on cognitive function.


  • Efficacy and safety of mirikizumab in psoriasis: a systematic review and meta-analysis of randomized controlled trials

    by Mable Pereira, Ancy Jenil Franco, Karthik Chintharala, Ana Carolina Putini Vieira, Ana Carolina Ventura de Santana de Jesus, Paweł Łajczak, Khaled Alhwaishel, Mario Saul Lira Castañeda, Elizabet Taylor Pimenta Weba, Kristian Reich

    Mirikizumab, an interleukin-23 (IL-23) p19 subunit inhibitor, has emerged as a promising treatment for moderate-to-severe plaque psoriasis. Despite its promising results, a comprehensive synthesis of clinical data is essential to assess its overall efficacy and safety profile. We searched PubMed, Embase, and Cochrane for studies assessing mirikizumab in moderate-to-severe psoriasis. A random-effects model using Inverse Variance (IV) computed mean differences (MD) for continuous outcomes and risk ratios (RR) for binary endpoints. Risk Difference (RD) studies were analysed using generic inverse variance (GIV) in Review Manager. Statistical analyses were conducted using R software version 4.2.1, following PRISMA guidelines. This analysis of three RCTs involving 1,649 adult patients over 16-52 weeks demonstrated mirikizumab's significant efficacy in treating psoriasis. At 16 weeks, mirikizumab substantially reduced Body Surface Area (BSA) to < 1% (RR: 34.53, p < 0.001) and improved PASI scores (PASI 100 RR: 25.94, PASI 90 RR: 11.50, PASI 75 RR: 10.47, all p < 0.001). Static Physician's Global Assessment (sPGA) scores of 0/1 were achieved (RR: 12.48, p < 0.001). Quality of life measures also improved significantly, with increases in SF-36 Physical and Mental Component Summaries (MD: 4.02 and 3.53 respectively, p < 0.01) and Dermatology Life Quality Index (DLQI) scores of 0/1 (RD: 0.51, p < 0.00001). Importantly, the safety profile of mirikizumab was comparable to the control, with no significant differences in the overall incidence of adverse effects (RR: 0.97; 95% CI: 0.86-1.10) or in serious adverse effects (RR: 1.61; 95% CI: 0.55-4.73). These results collectively demonstrate the efficacy and safety of mirikizumab in treating psoriasis, with significant improvements across multiple clinical and quality-of-life measures. This meta-analysis demonstrates that mirikizumab significantly reduces psoriasis severity and improves quality of life, with a favourable safety profile. These findings support its use as a valuable treatment option for moderate-to-severe plaque psoriasis. Further research is needed to assess long-term outcomes and comparative effectiveness.


  • Toward a Frontierless Collaboration in Neurosurgery: A Systematic Review of Remote Augmented and Virtual Reality Technologies

    by Jhon E. Bocanegra-Becerra, José Luis Acha Sánchez, Adriam M. Castilla-Encinas, Wagner Rios-Garcia, Cristian D. Mendieta, Diego A. Quiroz-Marcelo, Khaled Alhwaishel, Luis Aguilar-Zegarra, Miguel Angel Lopez-Gonzalez